This was my post on the 5/2/24 about the study. Did acknowledged...

This was my post on the 5/2/24 about the study. Did acknowledged that it did fall short of calling bis standard of care on prevent study only. They did not say it won't become standard of care and it certainly does not state BIS doesn't work (but as is common and usual it was looking forward to more studies emerging (they commented on one in denmark from memory using BIS). If you follow their guidelines lancet does imply BIS is first choice (if feasable/available) and to only use the others if BIS not available.

heres the post
"Big guideline updated appeared over the weekend. new mascc (international) guideline. Big update solely on the prevention of breast cancer related arm lymphoedema, lots of new information. Refer to page 7 for key recommendation. Very clear on the need for surveillance program. Also clear that bioimpedance is preferred for measurements, “arm circumference (or volumetric) or lymphangiography/lymphoscintigraphy measurement is an alternative method to identify patients with subclinical/early stage lymphoedema for early treatment when bioimpedance spectroscopy is not available or there areresource limitations”. Does stop short short of calling bioimpedance standard of care (committee was reluctant to pull the trigger on this statement from prevent study only). However clear that survellience programs need to commence now and bioimpedance is most studied and preferred option. Also remember this is an international guideline so many countries have more limited resources than US. However it also is relevant to wealthy developed international countries across Europe, Pacific, Asia, Canada etc. will help put bioimpedamce internationally on the map.
Good luck to all ."